/BCRX
BCRX Stock - BioCryst Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$7.41+1.65%
+$0.12 (+1.65%) • Dec 19
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.41
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+94.3%upside
Target: $14.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BCRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.34 – $7.48
TARGET (TP)$14.40
STOP LOSS$6.82
RISK/REWARD1:11.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$11.31
52W Low$6.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M |
| Gross Profit | $438.23M | $326.75M | $264.23M | $149.91M | $16.14M |
| Gross Margin | 97.2% | 98.6% | 97.6% | 95.4% | 90.6% |
| Operating Income | $-2,543,000 | $-103,709,000 | $-148,435,000 | $-177,720,000 | $-174,757,000 |
| Net Income | $-88,881,000 | $-226,539,000 | $-247,116,000 | $-184,062,000 | $-182,814,000 |
| Net Margin | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% |
| EPS | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 |
Company Overview
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
78%
Hold / Neutral
2
22%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish2 Neutral/Bearish
Price Targets
$14
Average Target
↑ 92.0% Upside
Now
$8
Low
$14
Average
$30
High
Based on 13 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 15th 2025 | TD Cowen | Resumed | Buy | $30 |
| October 1st 2025 | Evercore ISI | Downgrade | In-line | $8 |
| April 29th 2025 | Cantor Fitzgerald | Initiation | Overweight | $20 |
| February 25th 2025 | Wedbush | Initiation | Outperform | $15 |
| November 20th 2023 | JP Morgan | Resumed | Overweight | $10 |
| September 18th 2023 | RBC Capital Mkts | Upgrade | Outperform | $10← $9 |
| August 4th 2023 | Jefferies | Upgrade | Buy | $11 |
| July 13th 2023 | BofA Securities | Upgrade | Buy | $10 |
| February 22nd 2023 | Needham | Upgrade | Buy | $14 |
| November 2nd 2022 | Evercore ISI | Upgrade | Outperform | $16← $14 |
| August 5th 2022 | Oppenheimer | Downgrade | Perform | - |
| August 5th 2022 | Evercore ISI | Downgrade | In-line | $14 |
| April 18th 2022 | Barclays | Downgrade | Equal Weight | $13← $22 |
| April 11th 2022 | BofA Securities | Downgrade | Neutral | $14← $21 |
Earnings History & Surprises
BCRXBeat Rate
50%
Last 18 quarters
Avg Surprise
+22.3%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$0.06
Q4 2025
EPS Surprise History
Q1 24
-16.7%
$-0.28vs$-0.24
Q2 24
+26.1%
$-0.17vs$-0.23
Q3 24
+68.4%
$-0.06vs$-0.19
Q4 24
0.0%
$-0.07vs$-0.07
Q1 25
-85.7%
$-0.13vs$-0.07
Q2 25
+100.2%
$0.00vs$-0.07
Q3 25
+400.0%
$0.15vs$0.03
Q4 25
-14.3%
$0.06vs$0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $0.05 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.07 | $0.06 | -14.3% | ✗ MISS |
Q3 2025 | Aug 4, 2025 | $0.03 | $0.15 | +400.0% | ✓ BEAT |
Q2 2025 | May 5, 2025 | $-0.07 | $0.00 | +100.2% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.07 | $-0.13 | -85.7% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2024 | Aug 5, 2024 | $-0.19 | $-0.06 | +68.4% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.24 | $-0.28 | -16.7% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.25 | $-0.19 | +24.0% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.30 | $-0.28 | +6.7% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $-0.19 | $-0.38 | -100.0% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | $-0.32 | $-0.23 | +28.1% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.36 | $-0.32 | +11.1% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.39 | $-0.40 | -2.6% | ✗ MISS |
Q1 2022 | Feb 23, 2022 | $-0.31 | $-0.40 | -29.0% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.30 | $-0.33 | -10.0% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Raises Price Target to $32
📈 PositiveBenzinga•Dec 15, 2025, 03:48 PM
Trading Halt: Halt status updated at 7:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 12, 2025, 12:15 PM
FDA Approves BioCryst's NDA For Use Of Oral Pellet Formulation Of Once-Daily ORLADEYO For Prophylactic Therapy In Pediatric Patients With Hereditary Angioedema Aged 2 To
📈 PositiveBenzinga•Dec 12, 2025, 12:02 PM
Trading Halt: Halted at 6:41:42 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 12, 2025, 11:41 AM
BioCryst Reports HSR Waiting Period Termination For Astria Acquisition As Company Targets Q1 2026 Merger Close
📈 PositiveBenzinga•Dec 3, 2025, 12:20 PM
BioCryst Pharmaceuticals Reports That Orladeyo Oral Granules Demonstrated Early And Sustained Reductions In HAE Attack Rates Over One Year In Pediatric Patients Aged 2 To
📈 PositiveBenzinga•Nov 6, 2025, 01:25 PM
Citizens Maintains Market Outperform on BioCryst Pharma, Lowers Price Target to $25
➖ NeutralBenzinga•Nov 5, 2025, 01:09 PM
Barclays Maintains Equal-Weight on BioCryst Pharma, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 4, 2025, 01:59 PM•Also:
Needham Maintains Buy on BioCryst Pharma, Lowers Price Target to $18
➖ NeutralBenzinga•Nov 4, 2025, 10:41 AM
BioCryst Pharma Raises FY2025 Sales Guidance from $580.000M-$600.000M to $590.000M-$600.000M vs $625.558M Est
➖ NeutralBenzinga•Nov 3, 2025, 12:01 PM
BioCryst Pharma Q3 Adj. EPS $0.16 Beats $0.04 Estimate, Sales $159.395M Miss $162.974M Estimate
➖ NeutralBenzinga•Nov 3, 2025, 12:00 PM
BioCryst Pharmaceuticals To Present Four Abstracts From Second Interim Analysis of APeX-P Trial At Annual Scientific Meeting Of The American College Of Allergy, Asthma & Immunology In Orlando, Florida
➖ NeutralBenzinga•Oct 23, 2025, 11:03 AM
TD Cowen Reinstates Buy on BioCryst Pharma, Announces $30 Price Target
📈 PositiveBenzinga•Oct 15, 2025, 02:15 PM
Cantor Fitzgerald Maintains Overweight on BioCryst Pharma, Raises Price Target to $26
📈 PositiveBenzinga•Oct 15, 2025, 02:11 PM
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $27
📈 PositiveBenzinga•Oct 15, 2025, 11:21 AM
Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $20
📈 PositiveBenzinga•Oct 15, 2025, 10:00 AM
BioCryst to buy Astria Therapeutics for $13 per share (update)
📈 PositiveSeeking Alpha•Oct 14, 2025, 11:58 AM•Also:
Trading Halt: Halt status updated at 7:15:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Oct 14, 2025, 11:15 AM
BioCryst to Acquire Astria Therapeutics for Mix Of Cash And stock At Implied Value Of $13/Share
➖ NeutralBenzinga•Oct 14, 2025, 11:02 AM•Also:
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 14, 2025, 10:55 AM
Frequently Asked Questions about BCRX
What is BCRX's current stock price?
BioCryst Pharmaceuticals, Inc. (BCRX) is currently trading at $7.41 per share. The stock has moved +1.65% today.
What is the analyst price target for BCRX?
The average analyst price target for BCRX is $14.40, based on 1 analyst.
What sector is BioCryst Pharmaceuticals, Inc. in?
BioCryst Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BCRX's market cap?
BioCryst Pharmaceuticals, Inc. has a market capitalization of $1.56 billion, making it a small-cap company.
Does BCRX pay dividends?
No, BioCryst Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
NTLA
Intellia Therapeutics, Inc.
$9.23
Mkt Cap: $1.0B
PHVS
Pharvaris N.V.
$25.59
Mkt Cap: $1.7B
STOK
Stoke Therapeutics, Inc.
$31.96
Mkt Cap: $1.8B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TRVI
Trevi Therapeutics, Inc.
$13.01
Mkt Cap: $1.7B
UPB
Upstream Bio, Inc.
$29.35
Mkt Cap: $1.6B
WVE
Wave Life Sciences Ltd.
$15.98
Mkt Cap: $2.6B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to BCRX for comparison